Most children who have had a definitive pull-through operation for Hirschsprung's disease (HD) have excellent results. In a minority of patients, constipation, encopresis, enterocolitis and motility disturbances are found on long-term follow-up [1]. The cause in some of the patients is believed to be internal anal sphincter (IAS) achalasia related to abnormal innervation of the sphincter and a resultant absence of the normal anorectal relaxation reflex [2]. Recently, Topical application of botulinum toxin to the anal canal has been shown to be an effective treatment for anal sphincter achalasia and chronic idiopathic constipation in children [3, 4]. Based on this information, the current study was performed to prospectively study the efficacy of botulinum toxin in the management of anal achalasia after pullthrough operations for HD.
Most children who have had a definitive pull-through operation for Hirschsprung's disease (HD) have excellent results. In a minority of patients, constipation, encopresis, enterocolitis and motility disturbances are found on long-term follow-up [1] . The cause in some of the patients is believed to be internal anal sphincter (IAS) achalasia related to abnormal innervation of the sphincter and a resultant absence of the normal anorectal relaxation reflex [2] . Recently, Topical application of botulinum toxin to the anal canal has been shown to be an effective treatment for anal sphincter achalasia and chronic idiopathic constipation in children [3, 4] . Based on this information, the current study was performed to prospectively study the efficacy of botulinum toxin in the management of anal achalasia after pullthrough operations for HD.
Topical botulinum toxin injection were applied to 16 children with symptoms of obstruction and constipation after transanal endorectal pull-through for HD. Evaluation of improvement in symptoms and anorectal manometry were performed for all patients' after a treatment 8 weeks.
At the 8-week evaluation, inspection revealed a symptomatic improvement in 13 patients (81.3%). The remaining three children who did not have a symptomatic improvement were considered treatment failures. Maximal resting pressure (MRP) and maximal squeeze pressure (MSP) ranged from 121 to 198 mm Hg and 175 to 243 mm Hg, respectively before injection of botulinum toxin. After treatment, the MRP was reduced to 157 AE 20 mm Hg ( p < 0.05). MSP was reduced to 200 AE 23 mm Hg ( p < 0.05). There were no systemic or local complications observed in any of the patients during the procedure. The patients were followed for mean of 16 AE 2 months. There were no relapses during this follow-up period.
The increased post-operative resting pressure mainly reflects internal sphincter dysfunction, causing functional obstruction in childhood. In the present preliminary study, there were not only documented lowering of the MRP and MSP, but there was also marked improvement in bowel evacuation and therefore quality of life. There was no adverse reaction in children who received a botulinum toxin injection. These results are encouraging us to use the botulinum toxin as a new therapeutic agent when obstructive symptoms appear after pull-through operations for HD in children. Further experience with a larger group of patients will be required to determine the appropriate use of botulinum toxin. A long-term follow-up is warranted. The incidence and aetiological and contributing factors associated with neonatal jaundice vary according to ethnical and geographical differences. 1 In our experience, clinically significant jaundice requiring intervention is common in our outpatient clinics in Turkey, so we aimed to determine the aetiology and incidence of neonatal hyperbilirubinemia in Turkish newborns. Full-term 646 newborns required therapeutic intervention for the treatment of clinically significant hyperbilirubinemia were studied prospectively between May 2001 and November 2004. Decision about therapeutic intervention were made by clinical judgement based on the infant's history, course and physical findings with the guidance of the report published by the American Academy of Pediatrics (AAP). 2 The data were analysed using the Statistical Packages for Social Sciences (SPSS) 11.5 for Windows. The results were analysed using 2 for nominal data. Kruskal-Wallis and Mann-Whitney U-tests were used as nonparametric tests. A p value of <0.05 was considered significant.
Our data suggest that 31% of the babies in neonatal intensive care unit were hospitalized for hyperbilirubinemia. Newborns received phototherapy with a median of 2 days (range 1-7 days) and hospitalized for 4 days (range 1-52 days). At the time of hospitalization, weight loss average (% of their birthweight) was 7.07 AE 4.77%. Table 1 shows the frequency of aetiological factors and associated maximum serum bilirubin (MaxSB) levels. An aetiological factor was identified in 398 (61.6%) and no aetiological factor was found in 248 (38.4%) newborns. The mean MaxSB level of all cases was 21.30 AE 4.49 mg/dl. ABO incompability was the most frequent cause in the study group. ABO incompatibility and prematurity were reported as commonest causes of hyperbilirubinemia by Dawodu et al. from United Arab Emirates (UAE) and by Guaran et al. from Australia. 3, 4 Differently, septicaemia and glucose-6-phosphate dehydrogenase (G6PD) deficiency were reported as major aetiological factors by Narang et al. from India and Ahmed et al. from Nigeria. 5, 6 The majority of newborns (72.2%) were admitted during the first week of life and the median age of admission was 6 days (range 6 h to 29 days). Among 22 babies hospitalized in the first day of their life, Rhesus (Rh) incompatibility was the most frequent aetiological factor (45.5%). Rhesusincompatible newborns were significantly younger than G6PD deficient and ABO incompatible newborns (p < 0.05), and babies with subgroup incompatibility, hypothyroidism, urinary tract infection (UTI) and dehydration (p < 0.01). Newborns with hypothyroidism and UTI were significantly older than other aetiological groups (p < 0.01). A total of 110 double volume exchange transfusions (ET) were performed in 95 newborns. The mean MaxSB of babies underwent ET was 27.19 AE 6.88 mg/dl. Newborns with G6PD deficiency and Rh incompatibility required more ET than other groups (p < 0.01). Exchange-related mortality had not been occured in our series. Six cases of kernicterus were encountered and brain damage associated with hyperbilirubinemia was demonstrated by magnetic resonance imaging in these babies. The mean MaxSB level of babies developed kernicterus were 43.41 AE 14.32 mg/ dl. In our unknown aetiology group, 94.2% of babies were receiving breastfeeding and this frequency was higher from earlier reports. 5, 7 Recognizing aetiological factors that are significantly related to neonatal jaundice in our own community may allow a faster and suitable diagnostic approach to hyperbilirubinemic babies which helps to reduce mortality and morbidity, associated with neonatal hyperbilirubinemia, in developing countries. 
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